Certified by Founder Lodge
EQT Life Sciences
Netherlands - Amsterdam, North Holland
INVESTOR
1 Disclosed Funding Rounds $20,000,000
41 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
EQT Life Sciences, formerly LSP, is one of Europe’s largest and most experienced healthcare investors, targeting innovative life sciences and health care companies.
| Company | Date | Round | Raised |
|---|---|---|---|
 xilis |
July, 13 ,2022 | Series A | $89,000,000 |
 AstronauTx |
October, 09 ,2023 | Series A | $58,462,000 |
 Atalanta Therapeutics |
January, 29 ,2025 | Series B | $75,000,000 |
| Atalanta Therapeutics |
January, 29 ,2025 | Series B | $75,000,000 |
 Mosanna Therapeutics |
June, 10 ,2025 | Series A | $80,000,000 |
 Shinobi Therapeutics |
December, 13 ,2023 | Series A | $51,000,000 |
| Mosanna Therapeutics |
June, 10 ,2025 | Series A | $80,000,000 |
 FundamentalVR |
August, 11 ,2022 | Series B | $20,000,000 |
 QurAlis |
March, 10 ,2023 | Series B | $88,000,000 |
 LUMA Vision |
December, 19 ,2023 | Series A | $22,000,000 |
 Cyted Health |
September, 03 ,2025 | Series B | $44,000,000 |
| xilis |
July, 13 ,2022 | Series A | $89,000,000 |
| Atalanta Therapeutics |
January, 29 ,2025 | Series B | $75,000,000 |
 Evommune |
April, 27 ,2023 | Series B | $50,000,000 |
| Mosanna Therapeutics |
June, 10 ,2025 | Series A | $80,000,000 |
| AstronauTx |
October, 09 ,2023 | Series A | $58,462,000 |
 Tubulis GmbH |
October, 16 ,2025 | Series C | $359,197,300 |
| Mosanna Therapeutics |
June, 10 ,2025 | Series A | $80,000,000 |
| Shinobi Therapeutics |
December, 13 ,2023 | Series A | $51,000,000 |
| QurAlis |
March, 10 ,2023 | Series B | $88,000,000 |
| Cyted Health |
September, 03 ,2025 | Series B | $44,000,000 |
 Electra Therapeutics |
October, 22 ,2025 | Series C | $183,000,000 |
| Evommune |
April, 27 ,2023 | Series B | $50,000,000 |
| LUMA Vision |
December, 19 ,2023 | Series A | $22,000,000 |
| AstronauTx |
October, 09 ,2023 | Series A | $58,462,000 |
| Atalanta Therapeutics |
January, 29 ,2025 | Series B | $75,000,000 |
| Tubulis GmbH |
October, 16 ,2025 | Series C | $359,197,300 |
| Mosanna Therapeutics |
June, 10 ,2025 | Series A | $80,000,000 |
| Shinobi Therapeutics |
December, 13 ,2023 | Series A | $51,000,000 |
| Cyted Health |
September, 03 ,2025 | Series B | $44,000,000 |
| Electra Therapeutics |
October, 22 ,2025 | Series C | $183,000,000 |
| Tubulis GmbH |
October, 16 ,2025 | Series C | $359,197,300 |
| LUMA Vision |
December, 19 ,2023 | Series A | $22,000,000 |
| Electra Therapeutics |
October, 22 ,2025 | Series C | $183,000,000 |
| Atalanta Therapeutics |
January, 29 ,2025 | Series B | $75,000,000 |
 Artios |
November, 18 ,2025 | Series D | $115,000,000 |
| Mosanna Therapeutics |
June, 10 ,2025 | Series A | $80,000,000 |
| Cyted Health |
September, 03 ,2025 | Series B | $44,000,000 |
| Tubulis GmbH |
October, 16 ,2025 | Series C | $359,197,300 |
| Electra Therapeutics |
October, 22 ,2025 | Series C | $183,000,000 |
| Artios |
November, 18 ,2025 | Series D | $115,000,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Govstream.ai | $3,600,000 | (Dec 5, 2025)
ZincFive, Inc. | $30,000,000 | (Dec 5, 2025)
imper.ai | $28,000,000 | (Dec 5, 2025)
SPhotonix Inc | $4,500,000 | (Dec 5, 2025)
Multifactor (YC F25) | $15,000,000 | (Dec 5, 2025)
